New Canadian Drug-Shortage Rules May Help Protect Access to Essential Treatments

October 19, 2026 | Advocacy | Treatment Access

For Canadians living with inherited metabolic disorders, reliable access to prescribed treatments can be essential. Recent changes to Canada's drug-shortage regulations may provide additional options when important medications are discontinued or become difficult to obtain.

On October 16, 2026, Health Canada published updated guidance explaining changes to Canada's drug-shortage and discontinuation regulations, which came into force on June 17, 2026.

Why medication shortages matter for rare diseases

People living with phenylketonuria (PKU), homocystinuria (HCU), maple syrup urine disease (MSUD), urea cycle disorders (UCDs) and related conditions may depend on specialized medications and medical nutrition products that have limited alternatives.

When a treatment becomes unavailable, switching medications may not be straightforward. Depending on the disorder and treatment involved, interruptions can create significant health risks.

What's changing in Canada?

1. Earlier notification of drug discontinuations

Manufacturers must report planned discontinuations at least 12 months in advance when the decision is made more than 12 months before discontinuation.

When discontinuation is planned within 12 months, reporting is required within five calendar days of the decision.

Earlier notification can provide additional time for healthcare providers, regulators and patients to prepare.

2. Expanded options for importing replacement medications

Health Canada's exceptional importation framework allows certain foreign-authorized medications to be considered as temporary substitutes when Canadian-authorized drugs become unavailable.

Under specified conditions, exceptional importation may now be permitted for up to 36 months following a Canadian product's discontinuation.

This may provide additional time to identify longer-term treatment and supply solutions.

3. Additional tools for responding to serious shortages

The updated framework expands certain regulatory mechanisms for managing drug supply disruptions and supporting access to appropriate alternatives.

What does this mean for inherited metabolic disorders?

For rare metabolic conditions, these changes may create additional options when essential medications are at risk of becoming unavailable.

One area of particular interest to the UCD community is access to specialized ammonia-management medications, including RAVICTI (glycerol phenylbutyrate).

Changes to the availability of these medications can create uncertainty for families and metabolic healthcare teams.

The expanded regulations may offer an additional avenue for examining possible supply solutions.

However, the new rules do not automatically guarantee access to any particular medication. Exceptional importation requires regulatory assessment, an appropriate product and participation by eligible suppliers.

These provisions concern drugs. Specialized medical foods and metabolic formulas may be subject to different regulatory arrangements.

What should families do if a medication becomes difficult to obtain?

Patients and caregivers should contact their metabolic clinic or pharmacist promptly if they become aware of a possible supply interruption.

Families should not change or discontinue prescribed metabolic treatments without guidance from their healthcare team.

Early communication can help clinicians explore appropriate alternatives and develop plans for continuity of care.

CanPKU+ perspective

Reliable treatment access is a central advocacy priority for CanPKU+.

For rare inherited metabolic disorders, preventing a medication shortage can be just as important as responding after one occurs.

CanPKU+ supports regulatory approaches that encourage earlier notification, improve communication and create additional pathways for maintaining access to essential therapies.

We will continue examining how these provisions may apply to treatments used by the communities we represent, including situations involving product discontinuation or limited Canadian supply.

Official sources

This article provides general regulatory information and does not confirm the availability of any specific treatment through exceptional importation.

Back to CARES - Advocacy/Plaidoyer